InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-14 | 2026-05-18 | Wurth Douglas Clark | Director | Purchase | 12.5K | $2.00 | $25K | 12.6K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $3.0M-12.2% | $3.5M-39.2% | $5.7M+37.6% | $4.2M |
| General and administrative | $3.9M+5.9% | $3.7M-14.5% | $4.3M-9.4% | $4.8M |
| Sales and marketing | $8K | — | $283K-37.2% | $451K |
| Total operating expenses | $7.0M-3.0% | $7.2M-30.5% | $10.3M+10.1% | $9.4M |
| Operating loss | -$7.0M+3.0% | -$7.2M+30.5% | -$10.3M-10.7% | -$9.3M |
| Interest expense | -$839+99.9% | -$823K | — | — |
| Interest income | $98K-33.1% | $146K-11.6% | $165K+83.9% | $90K |
| Other income, net | $8K-94.0% | $129K-32.9% | $192K+14.2% | $168K |
| Total other income (expense), net | $104K+119.1% | -$548K-253.4% | $357K+1615.6% | $21K |
| Net loss | -$6.8M+11.3% | -$7.7M+22.5% | -$10.0M-7.1% | -$9.3M |
| Deemed dividend on warrant modification | $13.2M | — | — | — |
| Net loss applicable to common stockholders | -$6.8M+67.3% | -$20.9M-110.4% | -$10.0M | — |
| Net Loss per share to common stockholders – Basic (in Dollars per share) | -$15.25+96.7% | -$456.75+87.4% | -$4K-39287.0% | -$9.22 |
| Net Loss per share to common stockholders – Diluted (in Dollars per share) | -$15.25+96.7% | -$456.75+87.4% | -$4K | — |
| Weighted average common shares outstanding – Basic (in Shares) | $449K+879.4% | $46K+1572.7% | $3K-99.7% | $1.0M |
| Weighted average common shares outstanding – Diluted (in Shares) | $449K+879.4% | $46K+1572.7% | $3K | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial